Overview

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to assess the expected biological equivalence between two formulations of insulin degludec/liraglutide (IDegLira) with identical active ingredient in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting
Liraglutide
Xultophy